A Global Vision Born Out of Personal Experience

Most of us are no more than one degree removed from someone who has suffered with cancer. The Human Genome Project gave many of us hope that we would one day find a cure for this deadly disease, and today many of those promising diagnostic technologies and therapeutics are finally coming to fruition.

Seven years ago, a group of individuals from the molecular diagnostics and lab services industry combined their passion for actualizing emerging discoveries in the field of molecular biology and cancer. We created a company focused on providing academic-level testing capabilities to physicians, which would benefit patients in every community in the U.S. Our goal was to ensure that patients throughout the country would all have the same access to critical diagnostic information, regardless of where they lived. This powerful information would allow treating clinicians to provide the most appropriate therapy and offer each patient the best chance of survival.

“At Clarient, we feel very fortunate that our vision of ‘bringing clarity to a complex disease’ has allowed us to touch more than 500,000 patients to date.”

— Ron Andrews

CEO, Clarient, Inc.

This idea was born out of personal experience with family members living in rural communities who had breast cancer and didn’t get the same level of care provided to those fortunate enough to live close to a major academic center. We began our quest with a clear understanding that the only difference between the physicians treating women with breast cancer in larger centers and those treating in the rural communities was access to the high-value diagnostic information that could enable the complete assessment of a cancer. We named the company that was created to fill this unmet need Clarient. In six short years, we have become one of the largest providers of molecular pathology testing services for breast cancer in the U.S., and have now expanded into a broad array of cancers.

Cancer is an extremely complex disease. With more than 400 therapeutics targeted at specific protein pathways in the pharma pipeline, physicians around the world will need to have access to information that only very sophisticated testing services can provide. These powerful therapeutics will be the inflection point taking us into an unprecedented era of personalized medicine.

At Clarient, we feel very fortunate that our vision of “bringing clarity to a complex disease” has allowed us to touch more than 500,000 patients to date, and has prepared us for what lies ahead. The world of cancer management will change significantly over the next 10 years, and now, as part of GE Healthcare, we believe we can become the most relevant cancer diagnostics company in the world.

When we started Clarient, many people said we had a big imagination. As part of GE, we know our vision of transforming cancer into a chronic disorder is achievable—and we now have a healthymagination!